1Moore MA. Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive Patient [J]. J Clin Hypertens,2001,3(1):37-44.
2Chanudet X, DeehampvaUins M. Antihypertensive otticacy and tolerability of low dose Perindopfii/indap-amide Combination Compared with Losartan in the treatment of essential hypertension[J]. Int J Clin Pract,2001,55(4):233-239.
3Sharma D, Buyse M, Pitt B, et al. Meta analysis of observed mortality data fron an-controlled, double-blind multiple-dose studies of Losartan in heart failure. Losartan Heart Failure Mortality Met,, analysis study Group[J]. Am J Cardiol,2001,87(2):187-192.
4Dunselman PH. Effects of the replacement of the angiotenain convertingenzyme inhibitor enalapfil by the angiotensin Ⅱ receptor blocker telmisartan in Patients with congestive heart failure [J]. Int J Cardiol,2001.77(2-3):131-140.
5Jalowy A, Sohulz R, Heusch G. ATt receptor blockade inexpetimentmyocardiol ischemia/reperfusion [J]. J Am Soc Nephrol, 1999, 10[Suppl 1]:S129-136.
6Tamiyana Y, Mofishita R, Nakagami H, et al. Potential Contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin Ⅱ blockade in Cardiomyopathy[J].Circulation, 2000,102(2):246-252.
7Dujardin KS,Enriquez-Sarano M,Bailey KR, et al.Effeet of Losartan on degree of mitral regurgitation quantified by echoeardiography [J].Am J Cardio1,2001,87(5):570-576.
8Noda K. Angiotensin receptor in the Lung[J] .Nippon Rinsho, 1999,57(5) : 1049-1053.
9Peters H, Border WA, Noble NA. Angiotensin Ⅱ blockade and low Protein diet Produce additive therapeutic effects in experimental glonerulonephritis[J]. Kidney Int,2000,57(4):1493-1501.
10Miyauchi N, Nakamura Y. Antiproteinuric effect of an angiotensin Ⅱreceptor antagonist in membranous nephropathy [J]. Nephron, 2001,88(2) :183-184.
